今年上半年，今海医疗科技实现收益2593.7万新加坡元，同比增加116.45%。其中，来自微创手术解决方案及医疗产品和相关服务费的收益由2023年上半年的40万新加坡元增加至2024年上半年的1230万新加坡元。值得一提的是，公司近来殊荣不断，今海医疗科技内窥镜方案于近期获选中国好医工“全国十佳医疗设备更新解决方案”。更早前，其内窥镜项目还荣获第十届中国医疗产业创新大赛“最具投资价值奖”。Jinhai Med Tech (02225) soared by more than 6%, as of the time of publication, it rose by 4.1%, closing at HK$6.35, with a turnover of HK$8.5101 million.
According to the IT Finance APP, Jinhai Med Tech (02225) soared by more than 6%, as of the time of publication, it rose by 4.1%, closing at HK$6.35, with a turnover of HK$8.5101 million.
On the news side, in recent years, Jinhai Med Tech has made many important breakthroughs in the research and development of endoscope technology. The company's latest Endo Next series true 4K 3D 4MOS ultra-high-definition fluorescence endoscope system was successfully listed in July 2023. As of now, Jinhai Med Tech's 4K3D naked eye fluorescence endoscope camera system has obtained a Class II Medical Device License issued by the Shanghai Drug Administration, with multiple successful practical application cases.
In the first half of this year, Jinhai Med Tech achieved revenue of 25.937 million Singapore dollars, a year-on-year increase of 116.45%. Among them, revenue from minimally invasive surgical solutions and medical products and related service fees increased from 0.4 million Singapore dollars in the first half of 2023 to 12.3 million Singapore dollars in the first half of 2024. It is worth mentioning that the company has recently received numerous awards. Jinhai Med Tech's endoscopy solution was recently selected as one of the "Top Ten National Medical Equipment Renewal Solutions" by China's Good Medical Worker. Earlier, its endoscopy project also won the "Most Investable Award" at the 10th China Medical Industry Innovation Competition.
